two separate tactics being simultaneously employed by heb, discredit and expose the motives of your enemies and then build credibility for yourself, enlist all allies and remember to seek out your enemies, enemies for they may join your fight, 10/10 5 days big presentation.
possible major interviews a by product for heb
Hemispherx to Report on Physical and Quality of Life Improvements in Ampligen Treatment of Chronic Fatigue
PR Newswire - October 05, 1998 02:45
Hemispherx to Present at American Association for Chronic Fatigue Syndrome Research Conference
NEW YORK, Oct. 5 /PRNewswire/ -- Dr. David R. Strayer of Hemispherx Biopharma, Inc. (Amex: HEB) will present a paper at the October 10, 1998, session of the American Association for Chronic Fatigue Syndrome Research Conference that reviews physical performance, cognition and quality of life improvements derived from Ampligen(R) treatment in four separate clinical studies.
The clinical trials reviewed in the paper include three open-label studies and one placebo-controlled study, which together encompassed over 200 individuals meeting the Centers for Disease Control case definition for CFS. The four clinical studies utilized similar Ampligen(R) dosage levels, duration of therapy, data endpoints and collection intervals.
The studies employed a series of outcome parameters that have been used to study other seriously debilitating diseases and that in the case of the controlled clinical trial were part of a protocol conducted under an Investigational New Drug application authorized by the U.S. Food and Drug Administration (FDA), with approval of the relevant institutional review boards. The outcome parameters included Karnofsky Performance Scores, exercise treadmill testing, and SCL-90-R neurocognitive function evaluation.
Ampligen(R) is currently being evaluated in Phase III clinical trials and is also available under a cost-recovery program authorized by the FDA and administered in conjunction with Olsten Healthcare (NYSE: OLS). At the present time, there is no fully approved treatment specifically for CFS and to the Company's knowledge, Ampligen is the only drug authorized for Phase III clinical testing in CFS.
SOURCE Hemispherx Biopharma, Inc.
/CONTACT: William A. Carter, M.D., CEO and Chairman, 215-988-0080, or
Investors, Sharon Will, 212-572-0762, both of Hemispherx Biopharma; or Media,
William J. Jenks of Broadgate Consultants, 212-232-2222, for Hemispherx
Biopharma/
/Web site: hemispherx.com
(HEB OLS)
--------------------------------------------------------------------------------
|
